C^N) and (C^N^C) cyclometalated Au(III) represent a highly promising class of potential anticancer agents. We report here the synthesis of seven new cyclometalated Au(III) complexes with five of them bearing an acridine moiety attached via (N^O) or (N^N) chelates, acyclic amino carbenes (AAC) and Nheterocyclic carbenes (NHC). The antiproliferative properties of the different complexes were evaluated in vitro on a panel of cancer cells including leukaemia, lung and breast cancer cells. We observed a trend between the cytotoxicity and the intracellular gold uptake of some representative compounds of the series.
Introduction
The worldwide approval of cisplatin for the treatment of several cancers in the late 1970s was the starting point of the modern use of metal complexes in medicine. 1 However, the poor selectivity of cisplatin for cancer cells over healthy fast growing cells induces severe side effects which limits the dose of chemotherapy given to patients, 2 and both intrinsic and acquired resistance reduces the effectiveness of platinum-based drugs. 3 For these reasons there has been an increasing interest in the development of alternatives to platinum-based compounds for therapeutic purposes, including iron, copper, ruthenium, titanium and goldcomplexes. [4] [5] [6] [7] [8] In particular, cyclometalated gold(III) complexes have been attracting significant interest. 9, 10 Both bidentate, (C^N) or tridentate, (C^N^C), (C^N^N) or (N^C^N) cyclometalated ligands have been used to stabilize the gold(III) centre, enabling the study of fundamental organometallic reactions, the characterization of catalytic intermediates, and the development of photoluminescent materials and of anticancer drug candidates. [11] [12] [13] Henderson and coworkers introduced a series of neutral cyclometalated (C^N)Au(N^N) chelate complexes containing phenylenediamine and ethylenediamine moieties, with the nitrogen atoms bearing electron-withdrawing moieties. The derivatives were tested for their in vitro cytotoxicity against mouse leukaemia cells (P388) and some showed very promising results in comparison to cisplatin. Several different (C^N) cyclometalated ligands were used, including the 6-membered ring based on 2-benzyl pyridine, and more rigid 2-phenyl pyridine complexes, combined with (N^O) and (O^O) chelate ligands ( Figure 1, structures A -C) . 14, 15 Figure 1 . Examples of previously reported cyclometallated gold(III) complexes tested for anticancer purposes. [14] [15] [16] [17] [18] We have recently described the synthesis and anticancer activity of novel cyclometalated (C^N pz^C ) gold III complexes with acyclic amino carbene (AAC) ligands enabling the introduction of amines and amino ester derivatives in the [(C^N pz^C )Au(carbene)] + scaffold (Figure 1 , structures E and F). The antiproliferative screening of these complexes identified them as promising potential chemotherapeutic agents. 17, 18 Gold(III) N-heterocyclic carbene (NHC) complexes appear to be more stable towards reducing agents like GSH and are highly cytotoxic towards cancer cell lines; for example, complex F showed IC50 values in the micromolar and sub-micromolar range against a panel of cancer cell lines. 18 In spite of the structural and electronic similarity between gold(III) and platinum(II) compounds, the two metals appear to have very different intracellular targets and the binding of gold(III) complexes to DNA is often weak and reversible. 19 However, it is possible to enhance interactions of gold(III) complexes with doublestranded DNA by optimizing the choice of the ligand toward that application. 20
Acridines are known to bind to DNA by intercalation; by the direct insertion of the three planar aromatic rings in between the base pairs of DNA which causes unwinding of the double helix. 21, 22 For example, Janočková et al. synthesized a series of acridine analogues, (figure 2) and demonstrated their ability to inhibit cancer cell growth in acute promyelocytic leukaemia cells (HL60) with IC50 values in the low micromolar range. DNA binding studies towards calf thymus DNA showed a strong interaction through DNA intercalation resulting in the inhibition of certain enzymes such as topoisomerase 1 and 2. 21 Howell et al. also studied the DNA binding and in-vitro cytotoxicity of 9-aminoacridinecarboxamides ( Figure 2 ), towards various types of tertiary DNA structures. The derivatives were shown to target Gquadruplex structures with some selectivity. 23 There are also examples of acridine motifs being used to enhance the cytotoxicity of metal-based chemotherapeutic agents with platinum, iron, iridium or rhodium metal centres. In all cases, the presence of the acridine increased the interactions of the complexes with DNA. 24, 25 26 to the best of our knowledge, no gold(III)-acridine conjugates have been described so far. In the present article, we report on the synthesis and anticancer activity of cyclometalated gold(III) complexes decorated with acridinyl substituents, based on the starting materials 1 -3 ( Figure 2 ). We focus on (i) neutral (C^N)-(N^O) and (C^N)-(N^N) derivatives, and (ii) (C^N pz^C ) pincer complexes where the acridine functionality is joined by either an AAC or an NHC ligand. The complexes were tested for their cytotoxicity towards three cancer cell lines, namely lung adenocarcinoma (A549), breast cancer (MCF-7) and leukaemia (HL60). The DNA binding abilities of the complexes towards dsDNA was also investigated using DNA FRET-melting assays.
Results and discussion

Synthesis and characterization
demonstrating the formation of only one isomer in each case, as was also seen for the simpler (N^O) and (N^N) complexes 4-6.
Slow diffusion of light petroleum into dichloromethane solutions of complexes 7 and 9 yielded crystals suitable for X-ray diffraction ( Figure 3 ). In both compounds the square planar geometry of the gold(III) centres is slightly distorted due to the small bite angles of the cyclometalated ligand [respective C11-Au-N1 angles 81.1° (7) and 80.9° (9) ]. In 7, the acridine-substituted nitrogen atom is in trans position to the nitrogen of the cyclometalated ligand, placing it on the same side as the tert-butyl substituent, while the O atom, as the weakest trans influence ligand, is trans to the stronger C-donor. The adopted conformation is therefore a reflection of the electronic preferences. The acridine moiety is twisted out of the coordination plane, with an Au1-N2-C22-C23torsion angle of 110 °, presumably to avoid steric hindrance with the tert-butyl substituent. As suggested by the NMR spectra, only one isomer of the complex was obtained.
In complex 9, on the other hand, the second ligand is an N^N chelate, with both donor atoms having similar electronic properties. Therefore, in this case a conformation is adopted which places the acridine substituent distal from the t-butyl group, to minimise steric interactions. Here, too, the acridine moiety is twisted out of the coordination plane (torsion angle Au1-N3-C22-C23 67.3°). The pyrazine-based pincer complex (C^N pz^C )AuCl (3) was synthesized as reported previously. 27 Conversion of 3 into the cationic xylylisocyanide complex [(C^N pz^C )Au(CNxyl)] + , followed by reaction with 9-aminoacridine afforded the functionalized acyclic amino carbene complexes 10 (Scheme 3). The yield was reduced due to the competitive hydrolysis of the highly electrophilic isocyanide adduct to the gold(III) formamide byproduct, as previously observed. 17 cells (A549), breast adenocarcinoma (MCF-7), and promyelocytic leukaemia (HL60). The IC50, (the concentration at which cell viability is reduced to 50%), was then determined using a colorimetric MTS assay after 72 h of incubation, with the cisplatin included for comparison (see Experimental part for details). The results are summarized in Table 1 . Table 1 : Cytotoxic effects of complexes 1-11 and ligands L1 and L2 in comparison to cisplatin towards different human cancer cell lines after 72 h of incubation.
Complex
IC50 ± SD (µM) a A549
MCF-7 HL60
IC50values in the 2-10 µM range. Complexes 5, 7 and 8 showed particularly high toxicity with values between 2-4 µM. IC50 values for the A549 cell line were slightly higher, between 10-20 µM for all of the complexes. Here, the simpler structures, complexes 4 and 5 showed the greatest overall toxicity.
Changing the (C^N) cyclometalated ligand from the rigid 5-ring (phenyl pyridine)to the flexible 6-ring ligand (2-benzylpyridine) appeared to have no significant effect on the cytotoxicity of the complexes. For example, for the HL60 leukaemia cell line, complexes 4 and 5 have IC50values of 2.9 and 2.7 µM, respectively. The same trend was found for complexes 7(1.4 µM) and 8(1.5 µM). This is different to results obtained by Kilpin et al., who found that complexes containing a six-membered cyclometalated ring displayed higher cytotoxicity than those with a five-membered cyclometalated ring. 14 For all three cell lines, the (N^O) chelates appeared to be slightly more cytotoxic than the corresponding N^N chelates, which is in contrast to the values obtained for the free acridine ligands, L1
and L2. For example, for the A549 lung cancer cell line the (N^O) chelate, complex 4, has an IC50 of 12.7 µM, while the corresponding (N^N) chelate 6 has an IC50 of 22.7 µM. The same pattern can be seen for the acridine-functionalized derivatives: 7, the (N^O) chelate, is more toxic than its (N^N) analogue 9
against the all three cancer cell lines. Here the effect is most notable against the leukaemia HL60 cell line, (IC50 of 1.4 and 6.3 µM for 7 and 9, respectively).
As a comparison of complexes 4 versus 7 and 5 versus 8 shows, adding an acridine functionality appeared not to increase the overall cytotoxicity of the mono-cyclometalated (C^N)-(N^X) complexes.
This also holds for the (N^N) chelates 6 compared to 9, where the toxicity differences due to acridine are not significant.
The [(C^N pz^C )Au(III)(AAC)] + complex 10 showed a higher cytotoxicity than cisplatin against both the MCF-7 and the A549 cancer cell lines, although it showed reduced activity against the HL60 cells (20.7 µM). These values are in good agreement with data on AAC complexes we reported earlier, particularly when considering the amino ester derivatives (e.g. GlyOEt -IC50 values of 6.4, 13.0 and 16.7
µM for MCF-7, A549 and HL60 respectively). 17 The other (C^N pz^C ) pincer complex, 11 with acridine functionality bound to the NHC ligand, showed the highest overall toxicity, with values in the low µM regions for all three cell lines. It was more than ten times more toxic than cisplatin against MCF-7 cells and 3-4 times more toxic against the A549 and HL60 cell lines. Although our incubation time is longer (72 h instead of 24 h), it is interesting to note that 11 is active against A549 cells while the related Au I complex [Au(MeImAcr)2] + is not. 26b The higher cytotoxicity of the [(C^N pz^C )Au(NHC)] + complexes with respect to the [(C^N pz^C )Au(AAC)] + complexes is in line with our previous results. 17
Cellular uptake into MCF-7 cells
The cellular uptake and the accumulation of drugs inside the cell are both major factors that influence the cytotoxicity of prospective anticancer agents. 29 Inductively coupled plasma-mass spectrometry, (ICP-MS) was used to quantify the amount of intracellular gold and thus measure the amount of compound taken up by the cell. In order to see whether the cytotoxicity of the complexes was influenced by their ability to be taken up by the cell, complexes 2, 6, 7 and 11 were chosen for uptake studies, since they show a range of antiproliferative activities against MCF-7 cells ranging from poor (IC50 (2) The significance of the results was analysed by t-test. **p value < 0.01.
There was a clear correlation between cellular uptake and the in vitro cytotoxicity of the complexes, with the most cytotoxic complexes showing the highest levels of cell uptake (see Figure 6 and ESI, Figure S1 ). This suggests that the primary limitation for the poorly toxic complexes is their very low uptake into the cell. Such a correlation between cellular uptake and antiproliferative activity has also been observed for other gold complexes, including [(C^N pz^C )Au(NHC] + complexes. 18, 30 The increase in cell uptake seems to follow the increasing lipophilicity of the complexes, which might suggest an internalization via passive diffusion, reminiscent of the process recently reported by Casini et al. for a phosphine analogue of 2. 31
DNA binding assays
Acridine derivatives are known to interact with duplex DNA as well as higher order DNA structures and this can influence the cytotoxic properties of the compounds. 22, 23 DNA intercalators are of interest as probes in the study of ligand-DNA interactions and also as potential therapeutic agents. 32 interactions observed for 8 and 11 are due to mechanisms other than the simple intercalation of the acridine moiety. Overall, considering that 7 and 8 present very similar cytotoxicities but drastically different interactions with DNA, these data suggest that acridine-DNA interactions have little bearing on the cytotoxicity mechanism of this series of compounds.
Reaction with Glutathione
Reduction of gold(III) complexes by glutathione (GSH) to gold(I) and gold(0) products is a typical feature of this class of complexes. 34 The stability of 11 and 7 towards reduction by GSH was therefore explored by 1 H NMR spectroscopy. Each complex was mixed at room temperature with reduced GSH in a 1:1 mixture of DMSO-d6 and D2O and monitored by over time. We had previously shown that a benzimidazole-based NHC complex of (C^N pz^C )Au(III) (Figure 1 , structure F) is stable towards reduction by GSH. 18 By contrast, the acridine substituted [(C^N pz^C )Au(NHC)] + complex 11 appeared less stable, and over a 24 hour period the gradual formation of oxidized glutathione (GSSG) was observed, along with the disappearance of signals for reduced GSH ( Figure 6 ). One can hypothesize that the higher steric hindrance around gold due to the acridine substituent on the NHC could facilitate the protolytic Au-C bond cleavage leading to S-coordination of GSH and subsequent reduction of the gold(III) ion, following a reaction pathway similar to the one recently found for the reaction of adamantylthiol with (C^N^C)Au pincer compounds. 35 The same pattern was seen for the acridine substituted (C^N)-(N^O) chelate complex, 7 ( Figure S2 ). 
Conclusion
A new series of mono cyclometalated (C^N)(N^X)Au(III) complexes as well as two bis-cyclometalated (C^N pz^C ) pincer complexes were synthesized, with and without acridine functionality. These complexes were tested for their cytotoxicity towards three cancer cell lines. These studies identified complex 11, the NHC derivative, as the most promising candidate, with IC50 values in the low µM range for all three cell lines. However, the introduction of an acridine functionality did not appear to increase the cytotoxicity of the complexes. Cell uptake studies demonstrated a correlation between cellular uptake and the in vitro cytotoxicity of the complexes and indicated that cellular uptake is the primary limitation for non-toxic gold(III) complexes. DNA binding studies showed that two of the derivatives, complex 8 and the NHC derivative 11, demonstrate high levels of DNA stabilization suggestive of DNA intercalation. The lack of a correlation between the cytotoxicity data and the interaction with ds-DNA may suggest that the addition of the acridine moiety onto these scaffolds did not result in improved DNA targeting. Taken together, those data suggest that DNA is probably not the main target of that class of compounds and that more experiments are required to fully elucidate its involvement in the mechanism of action of these complexes.
Moreover, both the pincer NHC complex [(C^N pz^C )Au(NHC)] + 11 and the mono-cyclometalated (C^N)Au(N^O) derivative 7 were prone to reduction by glutathione at a time scale commensurate with incubation, which suggests that these compounds are reduced to gold(I) species in the cellular environment. Further work is required to investigate the localization and accumulation of those complexes within the cells and other possible modes of action of these complexes. 1, 2, 3 and 5 were synthesized following reported procedures. 15, 27, 36, 37 Synthesis of complex 4
Materials and methods
A mixture of 2-(4-t-butyl)phenyl pyridine gold dichloride, (1), (0.200 g, 0.418 mmol), 2-acetamidophenol (0.100 g, 0.661 mmol) and aqueous trimethylamine (2 mL) was refluxed in methanol (30 mL) for 30 min.
The reaction was then cooled and water (40 mL) was added causing an immediate orange precipitation.
The flask was then placed in the freezer for two days. The orange solid was filtered and purified by dissolving in minimal dichloromethane (2 mL) and precipitating the product with an excess of light 
Synthesis of complex 7
A mixture of 2-(4-t-butyl)phenyl pyridine gold dichloride, (1), (0.235 g, 0.491 mmol), ligand L1 (0.300 g, 1.048 mmol) and aqueous trimethylamine (2 mL) was refluxed in methanol (30 mL) for 30 min. The reaction was then cooled and water (40 mL) was added causing an immediate dark brown precipitation.
The flask was placed in the freezer for two days. The brown solid was filtered off and purified by dissolving in dichloromethane (2 mL 
Synthesis of complex 9
A mixture of 2-(4-t-butyl)phenyl pyridine gold dichloride, (1), (0.200 g, 0.418 mmol), ligand L2 (0.177 g, 0.620 mmol) and aqueous trimethylamine (2 mL) was refluxed in methanol (30 mL) for 30 min. The reaction was then cooled and water (40 mL) was added causing an immediate light brown precipitation.
The flask was then placed in the freezer for two days. The brown solid was then filtered and purified by dissolving in minimal dichloromethane (2 mL). The product was precipitated with an excess of light 
Synthesis of complex 10
A mixture of (C^N pz^C )AuCl, ( 
Synthesis of L1
2-(Acridin-9-ylamino)-benzoic acid (0.600 g, 2.100 mmol) and N,N'-carbonyldiimidazol(CDI) (0.341 g, 
X-ray crystallography
Description of the crystals: The crystals were mounted on a MiTeGen MicroMesh and fixed in a cold nitrogen stream. Diffraction intensities were recorded at 298, 173 or 140 K on a Rigaku HG Saturn724+ (2×2 bin mode) diffractometer or an Oxford Diffraction Xcalibur-3 instrument, both equipped with Mo-Kα radiation. Data collection, refinement and reduction were performed using the CrystalClear-SM Expert 3.1 b27 or CrysAlisPro software and the absorption correction was applied at this stage. 38 All structures were solved using SHELXS/T and refined by full-matrix least-squares methods on F 2 with SHELXL. 39 Non-hydrogen atoms were refined with anisotropic thermal parameters. Hydrogen atoms were included in idealised positions. No missed symmetry was reported by PLATON. 40 Computer programs used in this analysis were run through WinGX. 41 Scattering factors for neutral atoms were taken from reference. 42
Antiproliferation assay
The human A549 and HL60 cancer cell lines (from ECACC) were cultured in RPMI 1640 medium with 10% fetal calf serum, 2 mM L-glutamine, 100 U mL−1 penicillin and 100 µg mL−1 streptomycin 197 Au. Certified standards and independent reference were used for accuracy. Acid blanks were run through the system and subtracted from sample measurements before corrections for dilution.
FRET assay.
The initial FRET melting screen was performed using a fluorescence resonance energy transfer (FRET)
DNA melting based assay. The sequence used was DSFRET FAM-d(TAT-AGC-TAT-A-HEG(18)-TAT-AGC-TAT-A)-TAMRA-3′). The labelled oligonucleotide (donor fluorophore FAM is 6carboxyfluorescein; acceptor fluorophore TAMRA is 6-carboxytetramethyl-rhodamine) were prepared as a 220 nM solution in 10 mM sodium cacodylate buffer at the indicated pH with 100 mM sodium chloride and then thermally annealed. Strip-tubes (QIAgen) were prepared by aliquoting 20 μL of the annealed DNA, followed by 0.5 μL of the compound solutions. Control samples for each run were prepared with the same quantity of DMSO with the DNA in buffer. Fluorescence melting curves were determined in a QIAgen Rotor-Gene Q-series PCR machine, using a total reaction volume of 20.5 μL. Measurements were made with excitation at 470 nm and detection at 510 nm. Final analysis of the data was carried out using QIAgen Rotor-Gene Q-series software and Origin or Excel.
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